$11.240
-1.181 (-10.51%)收盤時
PLRZ 資訊
PLRZ 事件
Polyrizon Enters $4 Million Financing Agreement with Institutional Investor
Polyrizon announced that it has entered into definitive agreements with a single institutional investor for the purchase and sale of its Ordinary Shares and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also agreed to sell to the same investor pre-funded and investor warrants. Aggregate gross proceeds to the Company from both transactions are expected to be approximately $4.0 million. Aegis Capital Corp. is acting as exclusive placement agent for the offerings.
Polyrizon Completes Contracts for Nasarix Clinical Study
Polyrizon announced that it has completed contracting with the fourth and fifth clinical sites participating in its clinical study of Nasarix Allergy Blocker. With the execution of these final agreements, Polyrizon has completed the contracting with all five U.S. clinical sites selected for the study, marking an important operational milestone and moves the Nasarix program into study execution. The planned first-in-human study is a prospective, multicenter, randomized, single-blind, two-arm clinical trial designed to evaluate the efficacy, safety and tolerability of Nasarix in patients with seasonal allergic rhinitis. The study is designed to enroll up to 120 randomized patients, with subjects assigned in a 1:1 ratio to receive either Nasarix Allergy Blocker or an isotonic saline nasal spray control.
Polyrizon Completes Contracts for All Clinical Sites in NASARIX Study
Polyrizon has completed contracting with the fourth and fifth clinical sites participating in its clinical study of NASARIX Allergy Blocker. With the execution of these final agreements, Polyrizon has now completed the contracting process with all five clinical sites selected to participate in the study, marking an important operational milestone in the advancement of the NASARIX clinical program. The planned first-in-human study is a prospective, multicenter, randomized, single-blind, two-arm clinical trial designed to evaluate the efficacy, safety and tolerability of NASARIX in patients with seasonal allergic rhinitis. The study is designed to enroll up to 120 randomized patients, with subjects assigned in a 1:1 ratio to receive either NASARIX Allergy Blocker or an isotonic saline nasal spray control. The study's primary efficacy endpoint will evaluate the difference between the treatment groups in mean daily reflective Total Nasal Symptom Score over the first 14 treatment days. Safety assessments will include the frequency and severity of treatment-emergent adverse events as well as assessments of local and overall tolerability. Secondary efficacy measures are expected to include instantaneous Total Nasal Symptom Score, rhinoconjunctivitis-related quality of life, the number of symptom-free days, and use of permitted relief medication. Following completion of the clinical site contracting process, Polyrizon is advancing the study into the next stage of execution, including patient pre-screening activities and preparations for enrollment. Because the study evaluates seasonal allergic rhinitis under real-world allergen exposure conditions, patient enrollment is planned to coincide with the relevant allergy seasons. Local pollen counts and weather conditions will be monitored to assess airborne allergen exposure and support the timing of recruitment.
U.S. Stock Futures Slightly Higher, Tech Stocks Under Pressure
Stock futures are slightly higher, with pressure on technology and semiconductor names offset by steadier performance in other sectors. Technology leadership, particularly AI and semiconductor stocks, is showing some fatigue after a powerful second quarter rally. Chip shares experienced a notable pullback to begin the second half of the year, suggesting traders are taking profits after a strong run.Meanwhile, falling oil prices and easing geopolitical concerns have offered support to risk sentiment. Lower energy prices can help ease inflation pressures, potentially giving the Fed more flexibility later this year.The U.S. economy added 57,000 jobs in June, well below forecasts of 110,000 and a downwardly revised 129,000 in May. It is the lowest job gain in four months, but was roughly in line with the average monthly change over the prior 12 months. The unemployment rate dropped to 4.2% in June, down from 4.3% in May, as many people left the workforce.In pre-market trading, S&P 500 futures rose 0.35%, Nasdaq futures rose 0.54% and Dow futures rose 0.45%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Polyrizonup 8% after announcing results from its biocompatibility evaluation program for its proprietary Nasarix Allergy Blocker nasal sprayAeroVironmentup 5% after being awarded a $500M firm-fixed-price contract for the procurement of commercial counter-unmanned aerial systems and counter small-unmanned aerial systems capabilitiesRobinhoodup 3% after Mizuho raised the firm's price target on shares to $130 and maintained an Outperform rating on the sharesPalantirup 2% after DA Davidson upgraded the stock to Buy with a price target of $175, up from $165APi Groupup 1% after closing the acquisition of WTech Fire Group and boosting its FY26 outlookUP AFTER EARNINGS -Lindsayup 5%DOWN AFTER EARNINGS -Franklin Coveydown 19%LOWER -Bending Spoonsdown 6%, pulling back after its initial public offering yesterdayAlphabetdown 1% after the European Court of Justice confirmed the penalty imposed for Google Search's abuse of a dominant position in the context of the Android operating system
Polyrizon Completes Biocompatibility Evaluation for Nasarix
Polyrizon announced results from its biocompatibility evaluation program for its proprietary Nasarix Allergy Blocker nasal spray, with all required biological safety tests meeting their predetermined acceptance criteria. The evaluation program was designed in accordance with internationally recognized standards for biological safety assessment of medical devices, including the ISO 10993 series, FDA guidance, and applicable European regulatory requirements. The program was developed to assess the safety and biocompatibility profile of Nasarix, a drug-free mucoadhesive nasal spray intended to help reduce exposure to airborne allergens associated with seasonal allergic rhinitis. The completed testing program evaluated key biological safety endpoints identified for the device, including: cytotoxicity; sensitization; irritation / intracutaneous reactivity materialmediated pyrogenicity and acute systemic toxicity. In addition, long-term systemic toxicity was assessed through a toxicological risk assessment conducted in accordance with ISO 10993-17, demonstrating substantial safety margins across the product's constituent materials under intended conditions of use. The biocompatibility evaluation was based on the final Nasarix product configuration and supported by toxicological assessments of the formulation components, manufacturing processes, packaging materials, and intended patient exposure. According to the biological evaluation plan, the product consists of well-characterized materials with established safety profiles and utilizes a manufacturing process designed to minimize biological risk.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。